Benzinga··Vandana SinghGilead Bolsters Inflammation Arsenal With $1.675B Ouro Medicines Deal
Gilead acquires Ouro Medicines for $1.675B upfront, targeting inflammation pipeline expansion. Galapagos NV partners to co-develop lead asset OM336.
GILDACLXGLPGacquisitionorphan drug designation